Adoption of Innovative Radiation Therapy Technology Reinforces South Asian Cancer Center's Position as Pioneer in Patient Care SUNNYVALE, Calif. , Oct. 4, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the clinical team at Healthcare Global Enterprises (HCG) EKO,
Recently Published Data Demonstrate Benefits of CyberKnife Treatment for Both Low- and Intermediate-Risk Patients at Five Years Post-Treatment SUNNYVALE, Calif. , Sept. 25, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that published data from two prospective,
SUNNYVALE, Calif. , Aug. 16, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2018 . Q4 Fiscal 2018 and Recent Operating Highlights Gross orders increased 12 percent to $96.4 million Revenue increased to
Internationally Renowned Centre in Cambridge, England is First NHS Hospital to Install the Innovative Radiation Therapy System SUNNYVALE, Calif. , July 25, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Addenbrooke's Hospital clinical team has treated the first
SUNNYVALE, Calif. , July 19, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Joseph E. Whitters to the company's Board of Directors, effective as of July 16, 2018 . In addition, he will serve on the Board's Audit Committee. With Mr.
SUNNYVALE, Calif. , July 19, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its fourth quarter and fiscal year 2018 ended June 30, 2018 on Thursday, August 16, 2018 after the market close. Management will host a conference call to review the fourth quarter results
SUNNYVALE, Calif. , June 21, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Company has received an Atomic Energy Regulatory Board (AERB) Type Approval for its Radixact ® X9 System in India . The AERB Type Approval indicates the device conforms to established
SUNNYVALE, Calif. , May 30, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that recently published data from two new studies demonstrate the benefits of the TomoTherapy ® System in the delivery of total body irradiation (TBI), a procedure commonly used to prepare patients
- Results Demonstrate Exceptional Treatment Plan Quality Achievable with Accuray Treatment Planning Software (TPS) - Renowned Clinical Trials Group TROG Cancer Research and ProKnow Partnered to Host Study SUNNYVALE, Calif. , May 22, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY)
- One-of-a-kind Accuray Radixact® and CyberKnife® Systems Offer Technological Innovations Designed to Deliver Unique Patient Benefits - Mercy is First in Missouri to Acquire the Radixact and CyberKnife M6™ Systems SUNNYVALE, Calif. , May 9, 2018 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY)
*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.
